IonStar could upend industry standards, and quicken medical diagnosis and drug development
A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.
The groundbreaking tool, called IonStar, is the first to provide near-perfect accuracy when quantifying and comparing the abundance of proteins in the bodies of people who are healthy and ill.
Compared to industry standard MaxQuant, IonStar improved the measurement consistency of proteins in low abundance and lowered the amount of missing data in results from 17 percent to 0.1 percent, a level that has never been achieved with large samples.
The new tool could increase the quality and accuracy of medical diagnosis and quicken the pace of pharmaceutical development.
“IonStar will totally change the face of clinical and pharmaceutical research and industry, where large investigations are often critical,” says Jun Qu, PhD, lead investigator and professor in the UB School of Pharmacy and Pharmaceutical Sciences.
The research was published yesterday in the Proceedings of the National Academy of Sciences (PNAS).
Playing spot the difference
The abundance of proteins in the body that correspond with disease or pharmaceutical reactions can provide researchers with vital clues for accurately diagnosing a condition, and for developing potential therapies and evaluating drug effects.
Protein analysis tools are used to quantify and compare the abundance of proteins in groups of healthy individuals with those who are ill or treated with a drug. Changes in protein abundances, when analyzed together, often reveal novel biomarkers.
The challenge for researchers is that current tools are not efficient at analyzing large numbers of samples. One type of method, the labeling-method, uses chemical tags to label proteins. The issue: The software can only analyze up to 10 samples at a time, making it difficult for researchers to conduct typical pharmaceutical and clinical studies, says Qu.
The alternative, the label-free method, can analyze a large number of samples at once at the expense of accuracy and precision, causing researchers to waste time and resources validating falsely identified biomarkers.
IonStar increases accuracy and precision and lowers missing data by improving on sample preparation methods, alignment and feature detection designs for mass spectrometry analysis.
“For example, in clinical trials, comparing a handful of patients gets you nowhere,” says Qu. “If you can analyze a large number of patients with high-quality data, you can discover and track biomarkers much more accurately and reliably. The same is true for pharmaceutical investigations.”
Proving the concept in traumatic brain injury
Researchers used IonStar to quantify proteins in rats with traumatic brain injury, a debilitating condition that accounts for 2.2 million emergency room visits annually in the United States.
Using 100 tissue samples, IonStar identified 7,000 proteins, including 1,000 that differed in abundance, without missing data.
IonStar also measured low-abundance proteins with higher accuracy and precision than other prevalent analysis tools. This capability is critical, says Qu, because proteins that appear in smaller amounts play a more influential role in the body.
“If higher-level proteins are soldiers, then lower-level proteins are the commanders. They are the regulators that tell the higher-level proteins what to do,” says Qu.
Qu has used IonStar and similar techniques to analyze protein variation in cancer, diabetes, cardiovascular disease, neurodegeneration and retina degeneration as well.
Future work on IonStar will focus on expanding the number of samples the tool can analyze.
The Latest on: Drug development
via Google News
The Latest on: Drug development
CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease
on May 23, 2018 at 2:14 am
ROSTOCK, Germany--(BUSINESS WIRE)--May 23, 2018--CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced a clinical development collaboration with Orphazyme A/S (CPH: ORPHA ... […]
UsAgainstAlzheimer's Statement on Alzheimer's Drug Development
on May 22, 2018 at 8:09 am
"To each individual who participated in the atabecestat study and to their families and caregivers also impacted by the disease: thank you for your courage and dedication to finding a cure for Alzheimer's disease. Though you are surely disappointed, as we ... […]
Altogen Labs xenograft services for drug development studies of anti-cancer therapeutics
on May 21, 2018 at 10:48 am
AUSTIN, Texas, May 21, 2018 /PRNewswire/ -- Altogen Labs announced addition of five new in-house validated xenograft models (4T1, BxPC-3, Calu-6, MDA-MB-468, and PANC-1). This will make a total of 89 CDX xenograft models and 29 PDX xenograft models ... […]
GSK Updates Analytics Platform for Faster Drug Development
on May 21, 2018 at 7:11 am
GSK began an overhaul transformation of its R&D data and analytics infrastructure three years ago. Here's what it looks like today. Creating a new drug can take anywhere from 8 years to 20 years for a pharmaceutical company. To put that in perspective, on ... […]
Targeting Protein Kinases for Anti-Cancer Drug Development
on May 15, 2018 at 11:40 pm
A protein kinase, an enzyme, might be the key to developing new cancer drugs according to a research study at the University of Arizona. Creating a drug that utilizes these research findings will most likely take at least 10 years. However, there exists ... […]
The Revolution in Inflammation Drug Development
on May 15, 2018 at 11:44 am
Chronic autoimmune and inflammatory diseases are painful and often lifelong conditions. I know this both as a scientist and a father, as my son, Jeremy, was diagnosed 12 years ago with Crohn’s disease, one type of inflammatory bowel disease (IBD). […]
Ziopharm, Trump's Drug Pricing Plan And The Future Of Expensive Drug Development
on May 15, 2018 at 9:57 am
Ziopharm recently cancelled its phase III trial for an IL-12 treatment for glioblastoma brain cancer. Even though painful for shareholders, the decision was probably the correct one because a combination approach with Bristol Myers’ (BMY) Opdivo is much ... […]
Tagging Essential Malaria Genes to Advance Drug Development
on May 15, 2018 at 6:16 am
As a volunteer physician in a small hospital in Nigeria 30 years ago, I was bitten by lots of mosquitoes and soon came down with headache, chills, fever, and muscle aches. It was malaria. Fortunately, the drug available to me then was effective, but I was ... […]
via Bing News